Free tool
FAERS Monitor: Rezdiffra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217785 or its brand name (Rezdiffra, Resmetirom). Reports on generic versions are filed under their own applications.
Reports
2,298
Serious
834
36% of reports
Hospitalization
184
Death reported
125
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea368
- nausea320
- pruritus301
- hepatic cirrhosis175
- fatigue169
- alanine aminotransferase increased161
- aspartate aminotransferase increased149
- abdominal pain upper138
- weight decreased131
- dizziness125
- vomiting117
- abdominal pain103
- constipation102
- disease progression95
- hepatic enzyme increased90
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 285 |
| 2025 | 929 |
| 2026 | 1,081 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,861 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic cirrhosisSignal | 175 | 86.1 | 74.6 | 14,506 |
| aspartate aminotransferase increasedSignal | 149 | 25.7 | 22.0 | 3,518 |
| alanine aminotransferase increasedSignal | 161 | 24.1 | 20.7 | 3,537 |
| hepatic enzyme increasedSignal | 90 | 12.1 | 9.9 | 907 |
| disease progressionSignal | 95 | 7.4 | 6.0 | 518 |
| pruritusSignal | 301 | 7.2 | 6.5 | 1,621 |
| abdominal pain upperSignal | 138 | 6.1 | 5.2 | 594 |
| diarrhoeaSignal | 368 | 5.2 | 4.8 | 1,290 |
| weight decreasedSignal | 131 | 4.3 | 3.6 | 332 |
| constipationSignal | 102 | 4.3 | 3.5 | 256 |
| abdominal painSignal | 103 | 4.1 | 3.4 | 236 |
| nauseaSignal | 320 | 3.7 | 3.3 | 653 |
| dizzinessSignal | 125 | 2.3 | 1.9 | 92 |
| vomitingSignal | 117 | 2.3 | 1.9 | 84 |
| fatigue | 169 | 2.0 | 1.7 | 85 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.